NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE (norepinephrine bitartrate)
Norepinephrine bitartrate is a catecholamine used to raise blood pressure in adult patients experiencing severe, acute hypotension. It helps patients with acute hypotensive states by restoring blood pressure to more stable levels. This medication is typically used in critical care settings where a rapid cardiovascular response is necessary to maintain systemic circulation.
How NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE Works
This medication works by constricting peripheral blood vessels through alpha-adrenergic activity and stimulating the heart's contraction strength. It also dilates the coronary arteries via beta-adrenergic action, which helps improve blood flow to the heart muscle while increasing overall blood pressure.
Details
- Status
- Prescription
- First Approved
- 2021-01-15
- Patent Cliff
- 2041
- Routes
- INTRAVENOUS
- Dosage Forms
- SOLUTION
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE Approval History
What NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE Treats
1 indicationsNOREPINEPHRINE BITARTRATE IN 5% DEXTROSE is approved for 1 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Hypotension
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
3 of 16FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
3 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05997732 STARS | Pro00126600 | Ph 4 | recruiting | Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences |
| NCT05836272 EA-NE-TUN | Tunisian ICUs association | Ph 4 | recruiting | Early Administration of Norepinephrine in Sepsis |
| NCT05521152 | MD-12-2021 | Ph 3 | completed | Norepinephrine for Prevention of Intraoperative Hypotension in Infants Undergoing Kasai Portoenterostomy |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE FDA Label Details
Indications & Usage
FDA Label (PDF)NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE is indicated for the treatment of Hypotension.
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE Patents & Exclusivity
Patents (2 active)
Pro Intelligence Preview
Deep insights for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2041
- • 15 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 16 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.